{"gene":"SS18","run_date":"2026-06-10T07:46:41","timeline":{"discoveries":[{"year":2013,"finding":"SS18-SSX fusion protein competes with wild-type SS18 for assembly into BAF (mSWI/SNF) complexes, forming an altered complex that lacks the tumor suppressor BAF47 (hSNF5/SMARCB1). The altered SS18-SSX-containing BAF complex binds the Sox2 locus and reverses polycomb-mediated repression, activating Sox2 expression. Restoring wild-type SS18 concentration reassembles wild-type BAF complexes, retargets them away from the Sox2 locus, and restores polycomb repression of Sox2.","method":"Co-immunoprecipitation, ChIP-seq, RNAi knockdown, overexpression rescue experiments in SS cell lines","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, ChIP-seq, and functional rescue with multiple orthogonal methods; widely replicated by subsequent labs","pmids":["23540691"],"is_preprint":false},{"year":2018,"finding":"SS18-SSX globally retargets BAF complexes from enhancers to broad polycomb domains genome-wide, opposing PRC2-mediated repression and activating bivalent developmental genes. Upon SS18-SSX suppression, BAF47 reassembly restores enhancer activation, but BAF47 reassembly is not required for proliferative arrest.","method":"ChIP-seq, ATAC-seq, RNA-seq in primary SS tumors and cell lines with SS18-SSX knockdown/restoration","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal genomic methods, primary tumor validation, functional perturbation experiments","pmids":["29861296"],"is_preprint":false},{"year":2012,"finding":"SS18-SSX fusion protein forms a core complex bridging activating transcription factor 2 (ATF2) and transducin-like enhancer of split 1 (TLE1), resulting in repression of ATF2 target genes. siRNA knockdown of ATF2 or TLE1 rescues target gene expression and leads to growth suppression and apoptosis.","method":"Affinity purification/mass spectrometry of SS18-SSX complex, Co-IP, siRNA knockdown, gene expression profiling","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — complex purification by affinity/MS, reciprocal Co-IP, functional siRNA validation in multiple cell lines","pmids":["22439931"],"is_preprint":false},{"year":2012,"finding":"SS18 is a subunit specific to BAF-type (not PBAF-type) SWI/SNF complexes in human cells, co-purifying exclusively with ARID1A/BAF250a or ARID1B/BAF250b-containing complexes. Additional BAF-specific subunits identified by tandem affinity purification include SS18L1, DPF1, DPF2, DPF3, BRD9, BCL7A, BCL7B, and BCL7C.","method":"Tandem affinity purification followed by mass spectrometry (TAP-MS) in human cells","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — TAP-MS with 'complex walking' using multiple baits; defines subunit composition rigorously","pmids":["22442726"],"is_preprint":false},{"year":2013,"finding":"During neuronal development, SS18 is removed from BAF complexes and replaced by CREST at mitotic exit to form neuron-specific nBAF complexes. Knockdown of SS18 in neural stem cells causes cell-cycle exit and failure to self-renew, whereas continued SS18 expression in neurons blocks dendritic outgrowth.","method":"Proteomic analysis of BAF complex composition, kinetic assembly assays, SS18 knockdown in neural stem cells and neurons, differentiation of mouse ESCs and human fibroblasts to neurons","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Moderate — proteomic identification of subunit switch plus functional KD with specific phenotypic readouts in multiple cell types","pmids":["23785148"],"is_preprint":false},{"year":2018,"finding":"SS18-SSX1 physically interacts with KDM2B-PRC1.1 (a non-canonical polycomb repressive complex 1) and co-associates with both SWI/SNF and KDM2B complexes on unmethylated CpG islands. Via KDM2B, SS18-SSX1 aberrantly activates developmentally regulated polycomb target genes; KDM2B depletion restores repression and induces irreversible mesenchymal differentiation.","method":"Co-IP, ChIP-seq, functional genomics screen, KDM2B knockdown in SS cell lines","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — Co-IP, ChIP-seq, functional genomics with multiple orthogonal validations in a single lab","pmids":["29502955"],"is_preprint":false},{"year":2022,"finding":"SS18 assembles with BRG1 through a heterodimer interface structurally homologous to yeast SNF11/SNF2, suggesting SNF11 is a yeast homologue of SS18. The intrinsically disordered QPGY domain of SS18 undergoes liquid-liquid phase separation (LLPS) driven by tyrosine residues, and this phase separation recruits BRG1 into condensates. Both LLPS and BAF complex assembly are required for SS18-SSX oncogenic transformation of NIH3T3 cells.","method":"Crystal structure of SS18/BRG1 and SNF11/SNF2 subcomplexes, in vitro LLPS assays, tyrosine mutagenesis, NIH3T3 transformation assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure determination, in vitro reconstitution of phase separation, mutagenesis with functional readout; single lab but multiple orthogonal methods","pmids":["35585082"],"is_preprint":false},{"year":2021,"finding":"SS18-SSX expression in mouse mesenchyme leads to whole-complex degradation of canonical BAF (CBAF), with relative increases in PBAF and GBAF complex abundance. SMARCB1 is incorporated into both PBAF and CBAF complexes in the presence of SS18-SSX, and recombinant CBAF reconstitution shows equal SMARCB1 regardless of SS18 vs SS18-SSX inclusion, indicating the reduced SMARCB1 protein levels in synovial sarcoma derive from degradation of the whole CBAF complex driven by SS18-SSX.","method":"Genetic mouse models, recombinant CBAF reconstitution in human cells, quantitative proteomics of BAF complex subtypes, ChIP-seq","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — reconstitution experiments plus mouse genetics plus quantitative proteomics; multiple orthogonal approaches","pmids":["34078620"],"is_preprint":false},{"year":2021,"finding":"SS18 forms condensates in nuclei through a C-terminal intrinsically disordered region (IDR) rich in tyrosine residues. The IDR alone is insufficient to rescue the SS18-knockout pluripotent-to-somatic transition (PST) defect; the N-terminal 70 aa are additionally required for PST by interacting with the BAF complex. SS18 mediates BAF assembly through phase separation to regulate PST.","method":"CRISPR whole-genome screen, knockout rescue experiments with domain mutants, live-cell imaging of condensates, BAF complex Co-IP","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — CRISPR screen followed by domain dissection with multiple orthogonal methods including imaging and Co-IP","pmids":["34215745"],"is_preprint":false},{"year":2008,"finding":"SS18-SSX directly binds the EGR1 promoter and represses EGR1 expression. This SS18-SSX occupancy correlates with trimethylation of histone H3 Lys27 (H3K27me3) and recruitment of polycomb group proteins to the EGR1 promoter. HDAC inhibitor romidepsin reverts these chromatin modifications and reactivates EGR1.","method":"Chromatin immunoprecipitation (ChIP), histone modification analysis, romidepsin treatment in SS cell lines","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP and histone modification analysis showing direct promoter binding, single lab","pmids":["18519690"],"is_preprint":false},{"year":2006,"finding":"SS18-SSX2 expression affects histone modifications at the CD44 and IGF2 promoters and DNA methylation levels at the IGF2 imprinting control region, demonstrating epigenetic gene regulation by the fusion protein.","method":"Conditional SS18-SSX2 expression, cDNA microarray, chromatin immunoprecipitation, bisulfite sequencing for DNA methylation","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP and methylation analysis, single lab, inducible expression system","pmids":["17018603"],"is_preprint":false},{"year":2008,"finding":"SS18-SSX1 promotes p53 ubiquitination and degradation by stabilizing HDM2 through inhibition of HDM2 autoubiquitination, thereby negatively regulating p53 tumor-suppressive function.","method":"Overexpression and co-IP assays, ubiquitination assays, p53 stability/degradation assays in cell lines","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2-3 / Weak — Co-IP and ubiquitination assays, functional consequence shown, single lab","pmids":["18234968"],"is_preprint":false},{"year":2012,"finding":"SS18-SSX represses MCL1 and BCL2A1 anti-apoptotic genes by binding through ATF2 to cyclic AMP response elements (CRE) in their promoters and recruiting TLE1/Groucho. This direct transcriptional suppression renders synovial sarcoma cells sensitive to BH3-peptidomimetic ABT-263.","method":"ChIP at MCL1/BCL2A1 promoters, ATF2/TLE1 Co-IP, luciferase reporter assay, ABT-263 treatment in mouse and human SS cells and in vivo mouse model","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP and Co-IP with in vivo validation, single lab","pmids":["22797074"],"is_preprint":false},{"year":2016,"finding":"SS18-SSX interacts with TCF/LEF and TLE and HDAC but not with β-catenin in vivo, and induces Wnt target gene (AXIN2) expression by forming a promoter-bound complex containing TCF/LEF and HDAC, independent of β-catenin.","method":"Co-immunoprecipitation in vivo, ChIP at AXIN2 promoter, luciferase reporter assays","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2-3 / Weak — Co-IP and ChIP with reporter assays, single lab","pmids":["26905812"],"is_preprint":false},{"year":2006,"finding":"Disruption of the mouse Ss18 gene causes recessive embryonic lethality due to placental failure (impaired vascularization and/or chorio-allantoic fusion). Expression profiling of knockout embryos revealed altered expression of PPARBP (peroxisome proliferator-activated receptor-binding protein), suggesting functional co-linearity between SS18, p300, and PPARBP in placental development.","method":"Targeted gene disruption in mice (knockout), placental histology, expression profiling of knockout embryos, interbreeding with Ss18l1 mutants","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Moderate — rigorous mouse knockout with defined placental phenotype and expression profiling; loss-of-function with specific cellular readout","pmids":["16926188"],"is_preprint":false},{"year":2009,"finding":"SS18 (SYT) isoforms localize not only to the nucleus but also to the cytosol, where they associate with actin filaments and actin-associated proteins. RNAi ablation of SS18 isoforms impairs formation of stress fibers and focal adhesions and markedly reduces cell adhesion and spreading on fibronectin and laminin-111 but not on collagen types I or IV.","method":"Isoform-specific antibody staining, co-immunoprecipitation with actin, co-sedimentation assay, co-localization by fluorescence microscopy, RNAi knockdown with adhesion assays","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2-3 / Weak — Co-IP, co-sedimentation, RNAi with functional readout; single lab, one study","pmids":["19649286"],"is_preprint":false},{"year":2008,"finding":"The QPGY domain (carboxy half) of SS18 (SYT) is required for cyst growth in 3D MDCK cultures, while the amino-terminal region exerts a regulatory effect. SS18 facilitates ATP release into the extracellular space of polarized MDCK cells, activating purinergic P2Y receptor signaling to drive cystogenesis.","method":"3D collagen culture cystogenesis assay with domain-deletion mutants, ATP release measurement, P2Y receptor inhibition","journal":"Experimental cell research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — functional domain assay in MDCK cells with pharmacologic inhibition, single lab, single study","pmids":["18835266"],"is_preprint":false},{"year":2013,"finding":"SS18-SSX fusion protein displays a characteristic speckle pattern in the nucleus. Co-expression with a truncated SSX moiety (tSSX) shifts SS18-SSX localization from the speckle pattern to a diffuse pattern, suppresses cell proliferation, and reduces colony formation in synovial sarcoma cells.","method":"Fluorescence microscopy with tagged fusion proteins, co-transfection, proliferation and colony formation assays in SYO-1 and YaFuSS cells","journal":"PloS one","confidence":"Low","confidence_rationale":"Tier 3 / Weak — live-cell imaging with functional follow-up, single lab, single study","pmids":["24130893"],"is_preprint":false},{"year":2025,"finding":"WDR5 (a factor for H3K4 methylation) interacts with SS18-SSX and co-localizes with it at oncogene loci, where WDR5 promotes H3K4 methylation and chromatin association of SS18-SSX-containing chromatin-remodeling complexes. Pharmacologic PROTAC-mediated degradation of WDR5 suppresses SS18-SSX oncogenic programs and additionally causes ribosomal protein deregulation leading to p53 activation, suppressing SS growth in vitro and in vivo.","method":"Co-IP of WDR5 and SS18-SSX, ChIP-seq, PROTAC degradation, genomic profiling, in vitro and xenograft in vivo assays","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ChIP-seq plus in vivo functional validation, single lab","pmids":["40267190"],"is_preprint":false},{"year":2025,"finding":"SS18-SSX activates the SUMOylation program. The SUMOylation inhibitor TAK-981 de-SUMOylates the cBAF subunit SMARCE1, stabilizing cBAF on chromatin and shifting cells away from SS18-SSX-driven transcription. This leads to DNA damage and cell death in SS models.","method":"SUMOylation assays, SMARCE1 de-SUMOylation validation, ChIP-seq, in vitro and in vivo tumor models with TAK-981 treatment","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic pathway identified by multiple methods including ChIP-seq and in vivo validation, single lab","pmids":["41193430"],"is_preprint":false},{"year":2024,"finding":"SS18-SSX1 condensates recognize H2AK119ub histone modification (via the SSX moiety), which accounts for distinctive condensate properties compared to wild-type SS18. SS18-SSX1 condensates hijack wild-type SS18 condensates, relocating SS18 protein to H2AK119ub-marked loci targeted by SS18-SSX1, leading to downregulation of tumor suppressor genes (CAV1, DAB2) normally occupied by SS18.","method":"Small-molecule screening, mutant assays, live-cell condensate imaging, histone modification ChIP, gene expression analysis","journal":"Oncogenesis","confidence":"Medium","confidence_rationale":"Tier 2-3 / Weak — condensate imaging plus ChIP plus mutant assays, single lab, single study","pmids":["39468035"],"is_preprint":false},{"year":2022,"finding":"H3K27ac deposition guides rapid relocation of SS18/BAF complexes from pluripotent loci to AP-1 (JUN)-associated loci during JUN-induced pluripotent-to-somatic transition. The direct interaction between SS18/BAFs and JUN-centric protein complexes is undetectable by IP-MS, indicating H3K27ac acts as an indirect signal for BAF redistribution.","method":"ChIP-seq, ATAC-seq, IP-MS, BRG1 knockdown, JUN-inducible PST system","journal":"Cell & bioscience","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — multiple genomic methods plus IP-MS negative result, single lab","pmids":["35710570"],"is_preprint":false},{"year":2025,"finding":"SS18-SSX can activate oncogenic transcription independently of BAF complex ATPase activity. Targeted degradation of BAF ATPase subunits (SMARCA4) has modest effects on sarcoma cell viability and does not impede SS18-SSX target gene expression. SS18-SSX promotes transcription by engaging the histone acetyltransferase EP300 independently of BAF, and this activity depends on the C-terminal QPGY-rich domain of SS18.","method":"Targeted degradation of BAF ATPase subunits, SMARCA4 deletion in mouse tumor model, domain-specific SS18-SSX mutants, EP300 Co-IP, pharmacologic EP300/CREBBP degradation with functional readout","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods including in vivo mouse model and domain mutagenesis; preprint not yet peer-reviewed","pmids":["41659547"],"is_preprint":true},{"year":2025,"finding":"CBX4 (chromobox 4), a canonical polycomb repressive complex member, is a novel interactor of the SS18-SSX fusion oncoprotein, identified by immunoprecipitation-mass spectrometry using a fusion-junction-specific antibody across six synovial sarcoma cell lines.","method":"Immunoprecipitation-mass spectrometry using SS18-SSX fusion-junction antibody across 6 SS cell lines, immunohistochemistry on tissue microarray","journal":"Laboratory investigation","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — MS-based interactome with endogenous protein across multiple cell lines, single lab, no functional validation reported in abstract","pmids":["40992545"],"is_preprint":false},{"year":2022,"finding":"Proximity ligation assay (PLA) demonstrates physical interaction between SS18-SSX and the BAF complex member BRG1 in synovial sarcoma cells. ChIP with the SS18-SSX fusion-specific antibody confirms SS18-SSX occupancy at target gene promoters (TLE1, BCL2).","method":"Proximity ligation assay, chromatin immunoprecipitation with SS18-SSX fusion-junction-specific antibody","journal":"Applied immunohistochemistry & molecular morphology","confidence":"Medium","confidence_rationale":"Tier 2-3 / Weak — PLA and ChIP, single lab, confirmatory rather than novel","pmids":["35880992"],"is_preprint":false},{"year":2019,"finding":"SS18-SSX drives YAP/TAZ-TEAD transcriptional activity via an IGF-II/IGF-IR signaling loop that dysregulates Hippo effectors LATS1 and MOB1. RNAi knockdown of SS18-SSX reduces YAP/TAZ-TEAD transcriptional activity; conversely, SS18-SSX overexpression in mesenchymal stem cells induces aberrant YAP/TAZ-dependent signals.","method":"RNAi knockdown, SS18-SSX overexpression in mesenchymal stem cells, luciferase reporter for YAP/TAZ-TEAD, inhibitor treatment in vitro and in vivo xenograft/CAM models","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2-3 / Weak — functional KD and OE with reporter and pathway assays, in vivo confirmation, single lab","pmids":["30814111"],"is_preprint":false},{"year":2025,"finding":"SUMO2 inhibition by TAK-981 reduces global expression levels and chromatin occupancy of the SS18-SSX fusion protein with a concomitant reduction in H2AK119 ubiquitination (H2AK119ub), an epigenetic mark facilitating synovial sarcoma pathogenesis.","method":"CRISPR library screening, SUMO2 genetic depletion, TAK-981 pharmacologic inhibition, transcriptomic profiling, ChIP analysis","journal":"The EMBO journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR screen plus genetic and pharmacologic validation plus ChIP; single lab","pmids":["40804185"],"is_preprint":false}],"current_model":"SS18 is a BAF-subtype-specific subunit of mammalian SWI/SNF (mSWI/SNF) chromatin remodeling complexes that undergoes liquid-liquid phase separation through its intrinsically disordered QPGY domain to recruit BRG1 and facilitate BAF assembly, and whose N-terminal 70 aa mediate BAF interaction; the oncogenic SS18-SSX fusion protein competes with wild-type SS18 for BAF incorporation, drives whole-complex degradation of canonical BAF (CBAF), globally retargets residual BAF complexes from enhancers to polycomb-repressed bivalent loci via interactions with KDM2B-PRC1.1 and TCF/LEF-TLE-HDAC complexes, activates Sox2 and other developmental genes, and can also activate transcription independently of BAF through recruitment of the histone acetyltransferase EP300 via its QPGY domain, while additionally promoting oncogenesis through ATF2-TLE1-mediated repression of anti-apoptotic genes, HDM2 stabilization, YAP/TAZ pathway activation, and SUMOylation-dependent maintenance of its chromatin occupancy."},"narrative":{"mechanistic_narrative":"SS18 is a BAF-subtype-specific subunit of mammalian SWI/SNF (mSWI/SNF) chromatin remodeling complexes, co-purifying exclusively with ARID1A/ARID1B-containing BAF (not PBAF) complexes [PMID:22442726]. It nucleates BAF assembly through two complementary modules: its N-terminal ~70 residues mediate direct interaction with the complex, while its C-terminal intrinsically disordered QPGY domain, rich in tyrosines, drives liquid-liquid phase separation that recruits the BRG1 ATPase into nuclear condensates [PMID:35585082, PMID:34215745]; structurally, SS18 contacts BRG1 through a heterodimer interface, and both phase separation and BAF assembly are required for function [PMID:35585082]. SS18 incorporation into BAF is developmentally regulated—it is exchanged for CREST at mitotic exit to form neuron-specific nBAF complexes, and SS18 loss in neural stem cells causes cell-cycle exit and self-renewal failure [PMID:23785148]; germline disruption of Ss18 in mice causes embryonic lethality from placental vascular failure [PMID:16926188]. The recurrent oncogenic SS18-SSX fusion subverts this biology: it competes with wild-type SS18 for BAF incorporation to form an altered complex lacking the tumor suppressor BAF47/SMARCB1 and drives whole-complex degradation of canonical BAF [PMID:23540691, PMID:34078620]. The fusion globally retargets residual BAF complexes from enhancers to polycomb-repressed bivalent domains, opposing PRC2 and activating developmental genes such as Sox2, in part through physical association with the KDM2B-PRC1.1 complex on unmethylated CpG islands [PMID:23540691, PMID:29861296, PMID:29502955]. SS18-SSX additionally represses target genes by bridging ATF2 and TLE1/Groucho, silencing anti-apoptotic MCL1 and BCL2A1 [PMID:22439931, PMID:22797074], and engages TCF/LEF-TLE-HDAC complexes to activate Wnt targets independent of β-catenin [PMID:26905812]. The fusion can also activate transcription independently of BAF ATPase activity by recruiting the histone acetyltransferase EP300 via the QPGY domain [PMID:41659547]. Its chromatin occupancy is reinforced by WDR5-promoted H3K4 methylation and by SUMOylation of cBAF subunits, and is sustained by oncogenic engagement of YAP/TAZ-TEAD signaling and HDM2-mediated p53 destabilization [PMID:18234968, PMID:40267190, PMID:41193430, PMID:30814111, PMID:40804185].","teleology":[{"year":2006,"claim":"Established that SS18 has an essential physiological role in development, answering whether the gene matters in vivo beyond its known fusion in sarcoma.","evidence":"Targeted Ss18 gene disruption in mice with placental histology and expression profiling","pmids":["16926188"],"confidence":"High","gaps":["Molecular mechanism linking SS18 loss to vascular/chorio-allantoic failure not resolved","Relationship of placental phenotype to BAF chromatin remodeling not established"]},{"year":2012,"claim":"Defined SS18 as a BAF-restricted (not PBAF) mSWI/SNF subunit, fixing its position in the chromatin remodeling machinery.","evidence":"Tandem affinity purification/mass spectrometry with complex walking in human cells","pmids":["22442726"],"confidence":"High","gaps":["Did not define which SS18 domains mediate BAF specificity","Functional contribution of SS18 to remodeling activity not assayed"]},{"year":2012,"claim":"Showed the oncogenic fusion acts as a repressive transcription factor scaffold, bridging ATF2 and TLE1 to silence target genes—an early mechanism for fusion-driven gene repression.","evidence":"Affinity purification/MS, reciprocal Co-IP, siRNA knockdown and expression profiling in SS cell lines","pmids":["22439931","22797074"],"confidence":"High","gaps":["Relationship between this repressive complex and BAF incorporation not integrated","Genome-wide scope of ATF2/TLE1-mediated repression not mapped"]},{"year":2013,"claim":"Demonstrated the core oncogenic mechanism: SS18-SSX competes with wild-type SS18 for BAF assembly, evicts BAF47/SMARCB1, and reverses polycomb repression at Sox2.","evidence":"Reciprocal Co-IP, ChIP-seq, RNAi, and overexpression rescue in synovial sarcoma cell lines","pmids":["23540691"],"confidence":"High","gaps":["Genome-wide retargeting pattern not yet established","Mechanism by which the altered complex evades polycomb not defined"]},{"year":2013,"claim":"Revealed developmentally programmed SS18 subunit exchange (SS18→CREST forming nBAF), establishing SS18 as a regulator of neural stem cell self-renewal and differentiation.","evidence":"Proteomic BAF composition analysis and SS18 knockdown in neural stem cells and neurons","pmids":["23785148"],"confidence":"High","gaps":["Signal triggering the SS18/CREST switch not identified","Connection to phase-separation behavior of SS18 not addressed"]},{"year":2018,"claim":"Mapped the genome-wide consequence of the fusion: global redistribution of BAF from enhancers to broad polycomb domains, and engagement of KDM2B-PRC1.1, explaining bivalent developmental gene activation.","evidence":"ChIP-seq, ATAC-seq, RNA-seq, Co-IP, and KDM2B knockdown in primary tumors and SS cell lines","pmids":["29861296","29502955"],"confidence":"High","gaps":["BAF47 reassembly shown dispensable for proliferative arrest, leaving the relevant effector unclear","How residual BAF is physically retargeted to polycomb loci not fully resolved"]},{"year":2021,"claim":"Showed the fusion drives degradation of the entire canonical BAF complex rather than selective subunit loss, reframing the basis of SMARCB1 reduction in synovial sarcoma.","evidence":"Mouse genetics, recombinant CBAF reconstitution, and quantitative proteomics of BAF subtypes","pmids":["34078620"],"confidence":"High","gaps":["Degradation machinery targeting CBAF not identified","Why PBAF/GBAF are spared not mechanistically explained"]},{"year":2021,"claim":"Established phase separation as the assembly principle: SS18's tyrosine-rich C-terminal IDR forms condensates while the N-terminal 70 aa engages BAF, both required for the pluripotent-to-somatic transition.","evidence":"CRISPR whole-genome screen, domain-mutant rescue, live-cell condensate imaging, and BAF Co-IP","pmids":["34215745"],"confidence":"High","gaps":["Quantitative contribution of condensation versus direct binding to remodeling not separated","In vivo relevance of condensates to endogenous BAF function not established"]},{"year":2022,"claim":"Provided the structural and biophysical basis for SS18-BRG1 assembly, showing a defined heterodimer interface and tyrosine-driven LLPS that recruits BRG1, both required for transformation.","evidence":"Crystal structures of SS18/BRG1 subcomplexes, in vitro LLPS assays, tyrosine mutagenesis, and NIH3T3 transformation","pmids":["35585082"],"confidence":"High","gaps":["Structure of the full SS18-containing BAF assembly not determined","How SS18-SSX alters condensate composition not addressed here"]},{"year":2024,"claim":"Linked condensate behavior to the fusion's targeting specificity: SS18-SSX condensates read H2AK119ub via the SSX moiety and hijack wild-type SS18 condensates to silence tumor suppressors.","evidence":"Small-molecule screening, mutant assays, live-cell condensate imaging, and histone-mark ChIP","pmids":["39468035"],"confidence":"Medium","gaps":["Single study without independent replication","Direct biophysical demonstration of H2AK119ub recognition by SSX not shown"]},{"year":2025,"claim":"Identified a BAF-ATPase-independent activation arm in which SS18-SSX recruits EP300 through the QPGY domain, separating fusion oncogenic transcription from remodeling activity.","evidence":"Targeted degradation of BAF ATPase subunits, SMARCA4 deletion in mouse tumors, domain mutants, and EP300 Co-IP (preprint)","pmids":["41659547"],"confidence":"Medium","gaps":["Preprint not yet peer-reviewed","Relative contribution of EP300 versus BAF-dependent activity to tumor maintenance not quantified"]},{"year":2025,"claim":"Uncovered cofactor and post-translational dependencies (WDR5-driven H3K4 methylation; SUMOylation) that sustain SS18-SSX chromatin occupancy, nominating druggable nodes.","evidence":"Co-IP, ChIP-seq, CRISPR screens, and pharmacologic degradation/inhibition (WDR5 PROTAC, TAK-981) with in vivo validation","pmids":["40267190","40804185","41193430"],"confidence":"Medium","gaps":["Direct versus indirect routes by which SUMOylation stabilizes fusion occupancy not fully separated","Whether these dependencies are specific to the fusion or shared with wild-type SS18 unclear"]},{"year":null,"claim":"How wild-type SS18 condensation and BAF assembly are physiologically regulated across tissues, and how the fusion's multiple parallel mechanisms (BAF retargeting, EP300 recruitment, ATF2/TLE repression, YAP/TAZ and p53 axes) are integrated into a single transforming program, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified hierarchy ranking the fusion's mechanistic arms","Cytosolic/actin-associated roles of SS18 (idx 15) not reconciled with nuclear BAF function","Regulation of endogenous SS18 condensate dynamics in normal development not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,2,12,13,22]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[6,8]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[3,6]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,8,17]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[8,20]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[15]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[15]}],"pathway":[{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[0,1,3,5]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,12,13,22]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[4,14]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,7]}],"complexes":["BAF (canonical mSWI/SNF)","nBAF (neuron-specific BAF)","KDM2B-PRC1.1","ATF2-TLE1 repressor complex"],"partners":["SMARCA4","ARID1A","ATF2","TLE1","KDM2B","EP300","WDR5","TCF/LEF"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q15532","full_name":"Protein SSXT","aliases":["Protein SYT","Synovial sarcoma translocated to X chromosome protein"],"length_aa":418,"mass_kda":45.9,"function":"Appears to function synergistically with RBM14 as a transcriptional coactivator. Isoform 1 and isoform 2 function in nuclear receptor coactivation. Isoform 1 and isoform 2 function in general transcriptional coactivation. Component of SWI/SNF chromatin remodeling subcomplex GBAF that carries out key enzymatic activities, changing chromatin structure by altering DNA-histone contacts within a nucleosome in an ATP-dependent manner (PubMed:29374058)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q15532/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SS18","classification":"Not Classified","n_dependent_lines":20,"n_total_lines":1208,"dependency_fraction":0.016556291390728478},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"ARID1A","stoichiometry":10.0},{"gene":"SMARCA4","stoichiometry":10.0},{"gene":"SMARCD1","stoichiometry":4.0},{"gene":"SMARCD2","stoichiometry":4.0},{"gene":"SMARCE1","stoichiometry":4.0},{"gene":"ACTG1","stoichiometry":0.2},{"gene":"CBX1","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/SS18","total_profiled":1310},"omim":[{"mim_id":"618502","title":"BRD4-INTERACTING CHROMATIN REMODELING COMPLEX-ASSOCIATED PROTEIN-LIKE; BICRAL","url":"https://www.omim.org/entry/618502"},{"mim_id":"612409","title":"RNA-BINDING MOTIF PROTEIN 14; RBM14","url":"https://www.omim.org/entry/612409"},{"mim_id":"606473","title":"SS18-LIKE GENE 2; SS18L2","url":"https://www.omim.org/entry/606473"},{"mim_id":"606472","title":"SS18L1 SUBUNIT OF BAF CHROMATIN REMODELING COMPLEX; SS18L1","url":"https://www.omim.org/entry/606472"},{"mim_id":"605690","title":"BRD4-INTERACTING CHROMATIN REMODELING COMPLEX-ASSOCIATED PROTEIN; BICRA","url":"https://www.omim.org/entry/605690"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SS18"},"hgnc":{"alias_symbol":["SYT","SMARCL1"],"prev_symbol":["SSXT"]},"alphafold":{"accession":"Q15532","domains":[{"cath_id":"1.20.5","chopping":"17-68","consensus_level":"high","plddt":93.2335,"start":17,"end":68}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15532","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q15532-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q15532-F1-predicted_aligned_error_v6.png","plddt_mean":53.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SS18","jax_strain_url":"https://www.jax.org/strain/search?query=SS18"},"sequence":{"accession":"Q15532","fasta_url":"https://rest.uniprot.org/uniprotkb/Q15532.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q15532/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q15532"}},"corpus_meta":[{"pmid":"23540691","id":"PMC_23540691","title":"Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma.","date":"2013","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/23540691","citation_count":378,"is_preprint":false},{"pmid":"29861296","id":"PMC_29861296","title":"The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma.","date":"2018","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/29861296","citation_count":227,"is_preprint":false},{"pmid":"32141887","id":"PMC_32141887","title":"A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma.","date":"2020","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32141887","citation_count":189,"is_preprint":false},{"pmid":"17334349","id":"PMC_17334349","title":"Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcoma.","date":"2007","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/17334349","citation_count":134,"is_preprint":false},{"pmid":"22439931","id":"PMC_22439931","title":"Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics.","date":"2012","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/22439931","citation_count":132,"is_preprint":false},{"pmid":"29502955","id":"PMC_29502955","title":"The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma.","date":"2018","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/29502955","citation_count":109,"is_preprint":false},{"pmid":"22442726","id":"PMC_22442726","title":"SS18 together with animal-specific factors defines human BAF-type SWI/SNF complexes.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22442726","citation_count":103,"is_preprint":false},{"pmid":"18519690","id":"PMC_18519690","title":"Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18519690","citation_count":95,"is_preprint":false},{"pmid":"23785148","id":"PMC_23785148","title":"Kinetic analysis of npBAF to nBAF switching reveals exchange of SS18 with CREST and integration with neural developmental pathways.","date":"2013","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/23785148","citation_count":89,"is_preprint":false},{"pmid":"17018603","id":"PMC_17018603","title":"The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation.","date":"2006","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17018603","citation_count":82,"is_preprint":false},{"pmid":"31094920","id":"PMC_31094920","title":"Microsecretory Adenocarcinoma: A Novel Salivary Gland Tumor Characterized by a Recurrent MEF2C-SS18 Fusion.","date":"2019","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31094920","citation_count":81,"is_preprint":false},{"pmid":"24166495","id":"PMC_24166495","title":"SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.","date":"2013","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/24166495","citation_count":80,"is_preprint":false},{"pmid":"32559341","id":"PMC_32559341","title":"When used together SS18-SSX fusion-specific and SSX C-terminus immunohistochemistry are highly specific and sensitive for the diagnosis of synovial sarcoma and can replace FISH or molecular testing in most cases.","date":"2020","source":"Histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/32559341","citation_count":74,"is_preprint":false},{"pmid":"34078620","id":"PMC_34078620","title":"A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18-SSX Induces Canonical BAF Destruction.","date":"2021","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/34078620","citation_count":46,"is_preprint":false},{"pmid":"35585082","id":"PMC_35585082","title":"Phase transition and remodeling complex assembly are important for SS18-SSX oncogenic activity in synovial sarcomas.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35585082","citation_count":40,"is_preprint":false},{"pmid":"30814111","id":"PMC_30814111","title":"SS18-SSX-Dependent YAP/TAZ Signaling in Synovial Sarcoma.","date":"2019","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30814111","citation_count":39,"is_preprint":false},{"pmid":"26571495","id":"PMC_26571495","title":"SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26571495","citation_count":37,"is_preprint":false},{"pmid":"34215745","id":"PMC_34215745","title":"SS18 regulates pluripotent-somatic transition through phase separation.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34215745","citation_count":36,"is_preprint":false},{"pmid":"22797074","id":"PMC_22797074","title":"SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas.","date":"2012","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/22797074","citation_count":34,"is_preprint":false},{"pmid":"24022186","id":"PMC_24022186","title":"The clinical implication of SS18-SSX fusion gene in synovial sarcoma.","date":"2013","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24022186","citation_count":34,"is_preprint":false},{"pmid":"29533464","id":"PMC_29533464","title":"Genetic analyses of undifferentiated small round cell sarcoma identifies a novel sarcoma subtype with a recurrent CRTC1-SS18 gene fusion.","date":"2018","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29533464","citation_count":33,"is_preprint":false},{"pmid":"24989082","id":"PMC_24989082","title":"SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1.","date":"2014","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/24989082","citation_count":32,"is_preprint":false},{"pmid":"26905812","id":"PMC_26905812","title":"The fusion protein SS18-SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26905812","citation_count":30,"is_preprint":false},{"pmid":"26259251","id":"PMC_26259251","title":"β-catenin stabilization enhances SS18-SSX2-driven synovial sarcomagenesis and blocks the mesenchymal to epithelial transition.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26259251","citation_count":30,"is_preprint":false},{"pmid":"27572315","id":"PMC_27572315","title":"Identification of SHCBP1 as a novel downstream target gene of SS18-SSX1 and its functional analysis in progression of synovial sarcoma.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27572315","citation_count":28,"is_preprint":false},{"pmid":"20198325","id":"PMC_20198325","title":"Downregulation of SS18-SSX1 expression in synovial sarcoma by small interfering RNA enhances the focal adhesion pathway and inhibits anchorage-independent growth in vitro and tumor growth in vivo.","date":"2010","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20198325","citation_count":28,"is_preprint":false},{"pmid":"23716114","id":"PMC_23716114","title":"Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma.","date":"2014","source":"Clinical orthopaedics and related research","url":"https://pubmed.ncbi.nlm.nih.gov/23716114","citation_count":27,"is_preprint":false},{"pmid":"22976541","id":"PMC_22976541","title":"Recurrent and novel SS18-SSX fusion transcripts in synovial sarcoma: description of three new cases.","date":"2012","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22976541","citation_count":27,"is_preprint":false},{"pmid":"24422953","id":"PMC_24422953","title":"Reappraisal of TLE-1 immunohistochemical staining and molecular detection of SS18-SSX fusion transcripts for synovial sarcoma.","date":"2013","source":"Pathology international","url":"https://pubmed.ncbi.nlm.nih.gov/24422953","citation_count":27,"is_preprint":false},{"pmid":"18234968","id":"PMC_18234968","title":"The oncoprotein SS18-SSX1 promotes p53 ubiquitination and degradation by enhancing HDM2 stability.","date":"2008","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/18234968","citation_count":25,"is_preprint":false},{"pmid":"34091760","id":"PMC_34091760","title":"Correlating SS18-SSX immunohistochemistry (IHC) with SS18 fluorescent in situ hybridization (FISH) in synovial sarcomas: a study of 36 cases.","date":"2021","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34091760","citation_count":25,"is_preprint":false},{"pmid":"18267106","id":"PMC_18267106","title":"Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18267106","citation_count":25,"is_preprint":false},{"pmid":"33394377","id":"PMC_33394377","title":"SS18 Break-Apart Fluorescence In Situ Hybridization is a Practical and Effective Method for Diagnosing Microsecretory Adenocarcinoma of Salivary Glands.","date":"2021","source":"Head and neck pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33394377","citation_count":25,"is_preprint":false},{"pmid":"15163009","id":"PMC_15163009","title":"A novel case of synovial sarcoma of the kidney: impact of SS18/SSX analysis of renal hemangiopericytoma-like tumors.","date":"2004","source":"Diagnostic molecular pathology : the American journal of surgical pathology, part B","url":"https://pubmed.ncbi.nlm.nih.gov/15163009","citation_count":24,"is_preprint":false},{"pmid":"11435705","id":"PMC_11435705","title":"Mapping and characterization of the mouse and human SS18 genes, two human SS18-like genes and a mouse Ss18 pseudogene.","date":"2001","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11435705","citation_count":23,"is_preprint":false},{"pmid":"28249647","id":"PMC_28249647","title":"A clinicopathologic study on SS18 fusion positive head and neck synovial sarcomas.","date":"2017","source":"Oral oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28249647","citation_count":23,"is_preprint":false},{"pmid":"31595587","id":"PMC_31595587","title":"Novel SS18-NEDD4 gene fusion in a primary renal synovial sarcoma.","date":"2019","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31595587","citation_count":22,"is_preprint":false},{"pmid":"16926188","id":"PMC_16926188","title":"Targeted disruption of the synovial sarcoma-associated SS18 gene causes early embryonic lethality and affects PPARBP expression.","date":"2006","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16926188","citation_count":21,"is_preprint":false},{"pmid":"32557980","id":"PMC_32557980","title":"Undifferentiated round cell sarcomas with novel SS18-POU5F1 fusions.","date":"2020","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/32557980","citation_count":20,"is_preprint":false},{"pmid":"15208645","id":"PMC_15208645","title":"A novel FISH assay for SS18-SSX fusion type in synovial sarcoma.","date":"2004","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/15208645","citation_count":20,"is_preprint":false},{"pmid":"37899499","id":"PMC_37899499","title":"Utility of Immunohistochemistry With Antibodies to SS18-SSX Chimeric Proteins and C-Terminus of SSX Protein for Synovial Sarcoma Differential Diagnosis.","date":"2023","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/37899499","citation_count":18,"is_preprint":false},{"pmid":"35690998","id":"PMC_35690998","title":"Microsecretory adenocarcinoma of the skin harboring recurrent SS18 fusions: A cutaneous analog to a newly described salivary gland tumor.","date":"2022","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/35690998","citation_count":18,"is_preprint":false},{"pmid":"24975049","id":"PMC_24975049","title":"Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma.","date":"2014","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/24975049","citation_count":17,"is_preprint":false},{"pmid":"18714179","id":"PMC_18714179","title":"Downregulation of SS18-SSX1 expression by small interfering RNA inhibits growth and induces apoptosis in human synovial sarcoma cell line HS-SY-II in vitro.","date":"2008","source":"European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)","url":"https://pubmed.ncbi.nlm.nih.gov/18714179","citation_count":16,"is_preprint":false},{"pmid":"39528099","id":"PMC_39528099","title":"Advances of SS18-SSX fusion gene in synovial sarcoma: Emerging novel functions and therapeutic potentials.","date":"2024","source":"Biochimica et biophysica acta. Reviews on cancer","url":"https://pubmed.ncbi.nlm.nih.gov/39528099","citation_count":15,"is_preprint":false},{"pmid":"28761985","id":"PMC_28761985","title":"Synovial sarcoma showing loss of a green signal in SS18 fluorescence in situ hybridization: a clinicopathological and molecular study of 12 cases.","date":"2017","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/28761985","citation_count":15,"is_preprint":false},{"pmid":"29408457","id":"PMC_29408457","title":"The pathogenic role of MEF2D-SS18 fusion gene in B-cell acute lymphoblastic leukemia.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29408457","citation_count":14,"is_preprint":false},{"pmid":"36162599","id":"PMC_36162599","title":"Frequent TRPS1 expression in synovial sarcoma is associated with SS18-SSX fusion oncoprotein activity.","date":"2022","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/36162599","citation_count":14,"is_preprint":false},{"pmid":"20594581","id":"PMC_20594581","title":"Diagnostic utility of dual-color break-apart chromogenic in situ hybridization for the detection of rearranged SS18 in formalin-fixed, paraffin-embedded synovial sarcoma.","date":"2010","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20594581","citation_count":14,"is_preprint":false},{"pmid":"32019274","id":"PMC_32019274","title":"Cooperation between SS18-SSX1 and miR-214 in Synovial Sarcoma Development and Progression.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32019274","citation_count":13,"is_preprint":false},{"pmid":"38972355","id":"PMC_38972355","title":"Undifferentiated Round Cell Sarcoma With CRTC1::SS18 Fusion: Expanding Clinicopathologic Features of a Rare Translocation Sarcoma With Prominent Desmoplastic Stroma.","date":"2024","source":"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc","url":"https://pubmed.ncbi.nlm.nih.gov/38972355","citation_count":13,"is_preprint":false},{"pmid":"35521683","id":"PMC_35521683","title":"Primary renal sarcoma with SS18::POU5F1 gene fusion.","date":"2022","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35521683","citation_count":12,"is_preprint":false},{"pmid":"34057377","id":"PMC_34057377","title":"CRTC1-SS18 Fusion Sarcoma With Aberrant Anaplastic Lymphoma Kinase Expression.","date":"2021","source":"International journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34057377","citation_count":10,"is_preprint":false},{"pmid":"17471153","id":"PMC_17471153","title":"Molecular detection of SS18-SSX fusion gene transcripts by cRNA in situ hybridization in synovial sarcoma using formalin-fixed, paraffin-embedded tumor tissue specimens.","date":"2007","source":"Diagnostic molecular pathology : the American journal of surgical pathology, part B","url":"https://pubmed.ncbi.nlm.nih.gov/17471153","citation_count":10,"is_preprint":false},{"pmid":"35556229","id":"PMC_35556229","title":"SS18-SSX drives CREB activation in synovial sarcoma.","date":"2022","source":"Cellular oncology (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/35556229","citation_count":9,"is_preprint":false},{"pmid":"35880992","id":"PMC_35880992","title":"Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma.","date":"2022","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/35880992","citation_count":9,"is_preprint":false},{"pmid":"16484776","id":"PMC_16484776","title":"Common origin of the human synovial sarcoma associated SS18 and SS18L1 gene loci.","date":"2006","source":"Cytogenetic and genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16484776","citation_count":9,"is_preprint":false},{"pmid":"21536237","id":"PMC_21536237","title":"Unknown partner for USP6 and unusual SS18 rearrangement detected by fluorescence in situ hybridization in a solid aneurysmal bone cyst.","date":"2011","source":"Cancer genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21536237","citation_count":9,"is_preprint":false},{"pmid":"35639915","id":"PMC_35639915","title":"An SS18::NEDD4 cutaneous spindled and epithelioid sarcoma: An hitherto unclassified cutaneous sarcoma, resembling epithelioid sarcoma with aggressive clinical behavior.","date":"2022","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35639915","citation_count":8,"is_preprint":false},{"pmid":"32559641","id":"PMC_32559641","title":"MDM2 amplification and fusion gene ss18-ssx in a poorly differentiated synovial sarcoma: A rare but puzzling conjunction.","date":"2020","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/32559641","citation_count":7,"is_preprint":false},{"pmid":"38798672","id":"PMC_38798672","title":"Synovial Sarcoma Chromatin Dynamics Reveal a Continuum in SS18:SSX Reprograming.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38798672","citation_count":7,"is_preprint":false},{"pmid":"34249705","id":"PMC_34249705","title":"Therapeutic Response of Soft Tissue Sarcoma With Novel SS18-POU5F1 Fusion: A Case Report.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34249705","citation_count":7,"is_preprint":false},{"pmid":"40267190","id":"PMC_40267190","title":"Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma.","date":"2025","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/40267190","citation_count":6,"is_preprint":false},{"pmid":"25959879","id":"PMC_25959879","title":"Detection of Rare Variant of SS18-SSX1 Fusion Gene and Mutations of Important Cancer-Related Genes in Synovial Sarcoma of the Lip: Gene Analyses of a Case and Literature Review.","date":"2015","source":"Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/25959879","citation_count":6,"is_preprint":false},{"pmid":"18835266","id":"PMC_18835266","title":"The proto-oncoprotein SYT (SS18) controls ATP release and regulates cyst formation by polarized MDCK cells.","date":"2008","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/18835266","citation_count":6,"is_preprint":false},{"pmid":"41193430","id":"PMC_41193430","title":"Targeting SUMOylation promotes cBAF complex stabilization and disruption of the SS18::SSX transcriptome in synovial sarcoma.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/41193430","citation_count":5,"is_preprint":false},{"pmid":"41330912","id":"PMC_41330912","title":"The fibroblast epigenome underlies SS18::SSX-mediated transformation in synovial sarcoma.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/41330912","citation_count":5,"is_preprint":false},{"pmid":"39468035","id":"PMC_39468035","title":"Condensate remodeling reorganizes innate SS18 in synovial sarcomagenesis.","date":"2024","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/39468035","citation_count":5,"is_preprint":false},{"pmid":"37357741","id":"PMC_37357741","title":"SS18-SSX Antibody: A Useful Tool to Save Time and Reduce Costs in Synovial Sarcoma Diagnosis. Proposal of a Novel Diagnostic Algorithm.","date":"2023","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/37357741","citation_count":5,"is_preprint":false},{"pmid":"38883782","id":"PMC_38883782","title":"Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial Sarcoma.","date":"2024","source":"Research square","url":"https://pubmed.ncbi.nlm.nih.gov/38883782","citation_count":4,"is_preprint":false},{"pmid":"29025595","id":"PMC_29025595","title":"First cloned human immortalized adipose derived mesenchymal stem-cell line with chimeric SS18-SSX1 gene (SS-iASC).","date":"2017","source":"Cancer genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29025595","citation_count":4,"is_preprint":false},{"pmid":"30680066","id":"PMC_30680066","title":"Proteomic signatures corresponding to the SS18/SSX fusion gene in synovial sarcoma.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/30680066","citation_count":4,"is_preprint":false},{"pmid":"24130893","id":"PMC_24130893","title":"Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24130893","citation_count":4,"is_preprint":false},{"pmid":"32691176","id":"PMC_32691176","title":"Primary monophasic synovial sarcoma of the cervical esophagus confirmed by detection of the SS18-SSX2 fusion transcripts: case report and literature review.","date":"2020","source":"Surgical case reports","url":"https://pubmed.ncbi.nlm.nih.gov/32691176","citation_count":4,"is_preprint":false},{"pmid":"29894696","id":"PMC_29894696","title":"Epigenetic ConFUSION: SS18-SSX Fusion Rewires BAF Complex to Activate Bivalent Genes in Synovial Sarcoma.","date":"2018","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/29894696","citation_count":4,"is_preprint":false},{"pmid":"36920288","id":"PMC_36920288","title":"Interdependence of SS18-SSX-driven YAP1 and β-Catenin Activation in Synovial Sarcoma.","date":"2023","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/36920288","citation_count":3,"is_preprint":false},{"pmid":"35710570","id":"PMC_35710570","title":"H3K27ac mediated SS18/BAFs relocation regulates JUN induced pluripotent-somatic transition.","date":"2022","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/35710570","citation_count":3,"is_preprint":false},{"pmid":"38391333","id":"PMC_38391333","title":"Poorly differentiated biphasic synovial sarcoma of the vulva, displaying SS18::SSX1 fusion and weak to absent (mosaic) INI1/SMARCB1 immunostaining: A rare case with literature review.","date":"2023","source":"Indian journal of pathology & microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/38391333","citation_count":3,"is_preprint":false},{"pmid":"27362474","id":"PMC_27362474","title":"Immunoreactivity of a Monoclonal Antibody to SS18-SSX Fusion Gene Product in Formalin-fixed Paraffin-embedded Synovial Sarcoma Tissue Section.","date":"2018","source":"Applied immunohistochemistry & molecular morphology : AIMM","url":"https://pubmed.ncbi.nlm.nih.gov/27362474","citation_count":3,"is_preprint":false},{"pmid":"39803293","id":"PMC_39803293","title":"The Potential of the Probiotic Isolate Lactobacillus plantarum SS18-50 to Prevent Colitis in Mice.","date":"2024","source":"Food science & nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/39803293","citation_count":3,"is_preprint":false},{"pmid":"40335789","id":"PMC_40335789","title":"SS18::POU5F1-fused sarcoma of the parotid with divergent ganglioneuromatous differentiation-a novel manifestation of a rare tumor.","date":"2025","source":"Virchows Archiv : an international journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/40335789","citation_count":3,"is_preprint":false},{"pmid":"29325767","id":"PMC_29325767","title":"Primary Synovial Sarcoma arising from gingivo-buccal sulcus harbouring SS18-SSX2 positive fusion transcript: The 1st reported case in English literature.","date":"2018","source":"Journal of stomatology, oral and maxillofacial surgery","url":"https://pubmed.ncbi.nlm.nih.gov/29325767","citation_count":3,"is_preprint":false},{"pmid":"40296913","id":"PMC_40296913","title":"The SS18-SSX fusion oncoprotein: Friend and foe in targeted therapy for synovial sarcoma.","date":"2025","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/40296913","citation_count":2,"is_preprint":false},{"pmid":"34673590","id":"PMC_34673590","title":"Expression of TLE1, INI1, β-catenin, Claudin1, CK7, CK19, SS18 and calponin in synovial sarcoma.","date":"2021","source":"Indian journal of pathology & microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/34673590","citation_count":2,"is_preprint":false},{"pmid":"36591871","id":"PMC_36591871","title":"SS18-SSX Expression in a Contemporary Cohort of Primary Renal Synovial Sarcoma: A Multi-Institutional Experience of Fourteen Patients.","date":"2023","source":"International journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/36591871","citation_count":2,"is_preprint":false},{"pmid":"40128131","id":"PMC_40128131","title":"SS18-SSX and SSX c-terminus antibodies for identification of specific fusion oncoprotein in mesenchymal neoplasms.","date":"2025","source":"Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/40128131","citation_count":2,"is_preprint":false},{"pmid":"34405607","id":"PMC_34405607","title":"[Expression of SS18-SSX fusion-specific antibody and SSX C-terminal antibody in synovial sarcoma and its diagnostic value].","date":"2021","source":"Zhonghua bing li xue za zhi = Chinese journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34405607","citation_count":2,"is_preprint":false},{"pmid":"38712286","id":"PMC_38712286","title":"Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial Sarcoma.","date":"2024","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/38712286","citation_count":2,"is_preprint":false},{"pmid":"40878061","id":"PMC_40878061","title":"Uterine Myxoid Mesenchymal Tumor With a Novel SS18::VEZF1 Gene Fusion, Lacking Worrisome Histological Features.","date":"2025","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/40878061","citation_count":2,"is_preprint":false},{"pmid":"19649286","id":"PMC_19649286","title":"Cytosolic SYT/SS18 isoforms are actin-associated proteins that function in matrix-specific adhesion.","date":"2009","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/19649286","citation_count":2,"is_preprint":false},{"pmid":"40804185","id":"PMC_40804185","title":"Targeting SUMO2 reverses aberrant epigenetic rewiring driven by SS18::SSX fusion oncoproteins and impairs sarcomagenesis.","date":"2025","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/40804185","citation_count":1,"is_preprint":false},{"pmid":"39449577","id":"PMC_39449577","title":"SS18-SSX Expression and Clinicopathologic Profiles in a Contemporary Cohort of Primary Paratesticular Synovial Sarcoma: A Series of Fourteen Patients.","date":"2024","source":"The American journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/39449577","citation_count":1,"is_preprint":false},{"pmid":"32981875","id":"PMC_32981875","title":"Calcifying synovial sarcoma of the tongue with SS18 rearrangement: a rare variant in a rare location.","date":"2020","source":"Oral surgery, oral medicine, oral pathology and oral radiology","url":"https://pubmed.ncbi.nlm.nih.gov/32981875","citation_count":1,"is_preprint":false},{"pmid":"41440042","id":"PMC_41440042","title":"SS18::SSX and BRD9 Modulate Synovial Sarcoma Differentiation.","date":"2025","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/41440042","citation_count":0,"is_preprint":false},{"pmid":"39707021","id":"PMC_39707021","title":"SS18-SSX drives TYK2 expression to activate STAT3/Bcl2 axis, facilitating apoptosis evasion and advancing synovial sarcoma progression.","date":"2024","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/39707021","citation_count":0,"is_preprint":false},{"pmid":"37879825","id":"PMC_37879825","title":"Synovial sarcoma with ossification and calcification with SS18 immunochemical expression and rearrangement by fluorescent in situ hybridization.","date":"2023","source":"Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia","url":"https://pubmed.ncbi.nlm.nih.gov/37879825","citation_count":0,"is_preprint":false},{"pmid":"41659547","id":"PMC_41659547","title":"BAF complex-independent gene activation by SS18::SSX.","date":"2026","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/41659547","citation_count":0,"is_preprint":false},{"pmid":"41731718","id":"PMC_41731718","title":"Coexisting SS18::SSX Fusion and BCOR Overexpression: Unmasking a Primary Renal Synovial Sarcoma Amid Diagnostic Pitfalls.","date":"2026","source":"International journal of surgical pathology","url":"https://pubmed.ncbi.nlm.nih.gov/41731718","citation_count":0,"is_preprint":false},{"pmid":"40992545","id":"PMC_40992545","title":"Chromobox 4 (CBX4) Is a Novel Interactor of SS18::SSX in Synovial Sarcoma.","date":"2025","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/40992545","citation_count":0,"is_preprint":false},{"pmid":"41971444","id":"PMC_41971444","title":"Case Report: SS18::POU5F1-fused sarcoma with Flexner-Wintersteiner rosettes: a clinicopathological analysis of a rare tumor in the submandibular gland.","date":"2026","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/41971444","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52469,"output_tokens":6760,"usd":0.129404,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15762,"output_tokens":4570,"usd":0.09653,"stage2_stop_reason":"end_turn"},"total_usd":0.225934,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2013,\n      \"finding\": \"SS18-SSX fusion protein competes with wild-type SS18 for assembly into BAF (mSWI/SNF) complexes, forming an altered complex that lacks the tumor suppressor BAF47 (hSNF5/SMARCB1). The altered SS18-SSX-containing BAF complex binds the Sox2 locus and reverses polycomb-mediated repression, activating Sox2 expression. Restoring wild-type SS18 concentration reassembles wild-type BAF complexes, retargets them away from the Sox2 locus, and restores polycomb repression of Sox2.\",\n      \"method\": \"Co-immunoprecipitation, ChIP-seq, RNAi knockdown, overexpression rescue experiments in SS cell lines\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, ChIP-seq, and functional rescue with multiple orthogonal methods; widely replicated by subsequent labs\",\n      \"pmids\": [\"23540691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SS18-SSX globally retargets BAF complexes from enhancers to broad polycomb domains genome-wide, opposing PRC2-mediated repression and activating bivalent developmental genes. Upon SS18-SSX suppression, BAF47 reassembly restores enhancer activation, but BAF47 reassembly is not required for proliferative arrest.\",\n      \"method\": \"ChIP-seq, ATAC-seq, RNA-seq in primary SS tumors and cell lines with SS18-SSX knockdown/restoration\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal genomic methods, primary tumor validation, functional perturbation experiments\",\n      \"pmids\": [\"29861296\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SS18-SSX fusion protein forms a core complex bridging activating transcription factor 2 (ATF2) and transducin-like enhancer of split 1 (TLE1), resulting in repression of ATF2 target genes. siRNA knockdown of ATF2 or TLE1 rescues target gene expression and leads to growth suppression and apoptosis.\",\n      \"method\": \"Affinity purification/mass spectrometry of SS18-SSX complex, Co-IP, siRNA knockdown, gene expression profiling\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — complex purification by affinity/MS, reciprocal Co-IP, functional siRNA validation in multiple cell lines\",\n      \"pmids\": [\"22439931\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SS18 is a subunit specific to BAF-type (not PBAF-type) SWI/SNF complexes in human cells, co-purifying exclusively with ARID1A/BAF250a or ARID1B/BAF250b-containing complexes. Additional BAF-specific subunits identified by tandem affinity purification include SS18L1, DPF1, DPF2, DPF3, BRD9, BCL7A, BCL7B, and BCL7C.\",\n      \"method\": \"Tandem affinity purification followed by mass spectrometry (TAP-MS) in human cells\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — TAP-MS with 'complex walking' using multiple baits; defines subunit composition rigorously\",\n      \"pmids\": [\"22442726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"During neuronal development, SS18 is removed from BAF complexes and replaced by CREST at mitotic exit to form neuron-specific nBAF complexes. Knockdown of SS18 in neural stem cells causes cell-cycle exit and failure to self-renew, whereas continued SS18 expression in neurons blocks dendritic outgrowth.\",\n      \"method\": \"Proteomic analysis of BAF complex composition, kinetic assembly assays, SS18 knockdown in neural stem cells and neurons, differentiation of mouse ESCs and human fibroblasts to neurons\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — proteomic identification of subunit switch plus functional KD with specific phenotypic readouts in multiple cell types\",\n      \"pmids\": [\"23785148\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SS18-SSX1 physically interacts with KDM2B-PRC1.1 (a non-canonical polycomb repressive complex 1) and co-associates with both SWI/SNF and KDM2B complexes on unmethylated CpG islands. Via KDM2B, SS18-SSX1 aberrantly activates developmentally regulated polycomb target genes; KDM2B depletion restores repression and induces irreversible mesenchymal differentiation.\",\n      \"method\": \"Co-IP, ChIP-seq, functional genomics screen, KDM2B knockdown in SS cell lines\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ChIP-seq, functional genomics with multiple orthogonal validations in a single lab\",\n      \"pmids\": [\"29502955\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SS18 assembles with BRG1 through a heterodimer interface structurally homologous to yeast SNF11/SNF2, suggesting SNF11 is a yeast homologue of SS18. The intrinsically disordered QPGY domain of SS18 undergoes liquid-liquid phase separation (LLPS) driven by tyrosine residues, and this phase separation recruits BRG1 into condensates. Both LLPS and BAF complex assembly are required for SS18-SSX oncogenic transformation of NIH3T3 cells.\",\n      \"method\": \"Crystal structure of SS18/BRG1 and SNF11/SNF2 subcomplexes, in vitro LLPS assays, tyrosine mutagenesis, NIH3T3 transformation assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure determination, in vitro reconstitution of phase separation, mutagenesis with functional readout; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"35585082\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SS18-SSX expression in mouse mesenchyme leads to whole-complex degradation of canonical BAF (CBAF), with relative increases in PBAF and GBAF complex abundance. SMARCB1 is incorporated into both PBAF and CBAF complexes in the presence of SS18-SSX, and recombinant CBAF reconstitution shows equal SMARCB1 regardless of SS18 vs SS18-SSX inclusion, indicating the reduced SMARCB1 protein levels in synovial sarcoma derive from degradation of the whole CBAF complex driven by SS18-SSX.\",\n      \"method\": \"Genetic mouse models, recombinant CBAF reconstitution in human cells, quantitative proteomics of BAF complex subtypes, ChIP-seq\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — reconstitution experiments plus mouse genetics plus quantitative proteomics; multiple orthogonal approaches\",\n      \"pmids\": [\"34078620\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SS18 forms condensates in nuclei through a C-terminal intrinsically disordered region (IDR) rich in tyrosine residues. The IDR alone is insufficient to rescue the SS18-knockout pluripotent-to-somatic transition (PST) defect; the N-terminal 70 aa are additionally required for PST by interacting with the BAF complex. SS18 mediates BAF assembly through phase separation to regulate PST.\",\n      \"method\": \"CRISPR whole-genome screen, knockout rescue experiments with domain mutants, live-cell imaging of condensates, BAF complex Co-IP\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR screen followed by domain dissection with multiple orthogonal methods including imaging and Co-IP\",\n      \"pmids\": [\"34215745\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"SS18-SSX directly binds the EGR1 promoter and represses EGR1 expression. This SS18-SSX occupancy correlates with trimethylation of histone H3 Lys27 (H3K27me3) and recruitment of polycomb group proteins to the EGR1 promoter. HDAC inhibitor romidepsin reverts these chromatin modifications and reactivates EGR1.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP), histone modification analysis, romidepsin treatment in SS cell lines\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP and histone modification analysis showing direct promoter binding, single lab\",\n      \"pmids\": [\"18519690\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"SS18-SSX2 expression affects histone modifications at the CD44 and IGF2 promoters and DNA methylation levels at the IGF2 imprinting control region, demonstrating epigenetic gene regulation by the fusion protein.\",\n      \"method\": \"Conditional SS18-SSX2 expression, cDNA microarray, chromatin immunoprecipitation, bisulfite sequencing for DNA methylation\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP and methylation analysis, single lab, inducible expression system\",\n      \"pmids\": [\"17018603\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"SS18-SSX1 promotes p53 ubiquitination and degradation by stabilizing HDM2 through inhibition of HDM2 autoubiquitination, thereby negatively regulating p53 tumor-suppressive function.\",\n      \"method\": \"Overexpression and co-IP assays, ubiquitination assays, p53 stability/degradation assays in cell lines\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Weak — Co-IP and ubiquitination assays, functional consequence shown, single lab\",\n      \"pmids\": [\"18234968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SS18-SSX represses MCL1 and BCL2A1 anti-apoptotic genes by binding through ATF2 to cyclic AMP response elements (CRE) in their promoters and recruiting TLE1/Groucho. This direct transcriptional suppression renders synovial sarcoma cells sensitive to BH3-peptidomimetic ABT-263.\",\n      \"method\": \"ChIP at MCL1/BCL2A1 promoters, ATF2/TLE1 Co-IP, luciferase reporter assay, ABT-263 treatment in mouse and human SS cells and in vivo mouse model\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP and Co-IP with in vivo validation, single lab\",\n      \"pmids\": [\"22797074\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"SS18-SSX interacts with TCF/LEF and TLE and HDAC but not with β-catenin in vivo, and induces Wnt target gene (AXIN2) expression by forming a promoter-bound complex containing TCF/LEF and HDAC, independent of β-catenin.\",\n      \"method\": \"Co-immunoprecipitation in vivo, ChIP at AXIN2 promoter, luciferase reporter assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Weak — Co-IP and ChIP with reporter assays, single lab\",\n      \"pmids\": [\"26905812\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Disruption of the mouse Ss18 gene causes recessive embryonic lethality due to placental failure (impaired vascularization and/or chorio-allantoic fusion). Expression profiling of knockout embryos revealed altered expression of PPARBP (peroxisome proliferator-activated receptor-binding protein), suggesting functional co-linearity between SS18, p300, and PPARBP in placental development.\",\n      \"method\": \"Targeted gene disruption in mice (knockout), placental histology, expression profiling of knockout embryos, interbreeding with Ss18l1 mutants\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — rigorous mouse knockout with defined placental phenotype and expression profiling; loss-of-function with specific cellular readout\",\n      \"pmids\": [\"16926188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"SS18 (SYT) isoforms localize not only to the nucleus but also to the cytosol, where they associate with actin filaments and actin-associated proteins. RNAi ablation of SS18 isoforms impairs formation of stress fibers and focal adhesions and markedly reduces cell adhesion and spreading on fibronectin and laminin-111 but not on collagen types I or IV.\",\n      \"method\": \"Isoform-specific antibody staining, co-immunoprecipitation with actin, co-sedimentation assay, co-localization by fluorescence microscopy, RNAi knockdown with adhesion assays\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Weak — Co-IP, co-sedimentation, RNAi with functional readout; single lab, one study\",\n      \"pmids\": [\"19649286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The QPGY domain (carboxy half) of SS18 (SYT) is required for cyst growth in 3D MDCK cultures, while the amino-terminal region exerts a regulatory effect. SS18 facilitates ATP release into the extracellular space of polarized MDCK cells, activating purinergic P2Y receptor signaling to drive cystogenesis.\",\n      \"method\": \"3D collagen culture cystogenesis assay with domain-deletion mutants, ATP release measurement, P2Y receptor inhibition\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — functional domain assay in MDCK cells with pharmacologic inhibition, single lab, single study\",\n      \"pmids\": [\"18835266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"SS18-SSX fusion protein displays a characteristic speckle pattern in the nucleus. Co-expression with a truncated SSX moiety (tSSX) shifts SS18-SSX localization from the speckle pattern to a diffuse pattern, suppresses cell proliferation, and reduces colony formation in synovial sarcoma cells.\",\n      \"method\": \"Fluorescence microscopy with tagged fusion proteins, co-transfection, proliferation and colony formation assays in SYO-1 and YaFuSS cells\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — live-cell imaging with functional follow-up, single lab, single study\",\n      \"pmids\": [\"24130893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"WDR5 (a factor for H3K4 methylation) interacts with SS18-SSX and co-localizes with it at oncogene loci, where WDR5 promotes H3K4 methylation and chromatin association of SS18-SSX-containing chromatin-remodeling complexes. Pharmacologic PROTAC-mediated degradation of WDR5 suppresses SS18-SSX oncogenic programs and additionally causes ribosomal protein deregulation leading to p53 activation, suppressing SS growth in vitro and in vivo.\",\n      \"method\": \"Co-IP of WDR5 and SS18-SSX, ChIP-seq, PROTAC degradation, genomic profiling, in vitro and xenograft in vivo assays\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ChIP-seq plus in vivo functional validation, single lab\",\n      \"pmids\": [\"40267190\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SS18-SSX activates the SUMOylation program. The SUMOylation inhibitor TAK-981 de-SUMOylates the cBAF subunit SMARCE1, stabilizing cBAF on chromatin and shifting cells away from SS18-SSX-driven transcription. This leads to DNA damage and cell death in SS models.\",\n      \"method\": \"SUMOylation assays, SMARCE1 de-SUMOylation validation, ChIP-seq, in vitro and in vivo tumor models with TAK-981 treatment\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic pathway identified by multiple methods including ChIP-seq and in vivo validation, single lab\",\n      \"pmids\": [\"41193430\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SS18-SSX1 condensates recognize H2AK119ub histone modification (via the SSX moiety), which accounts for distinctive condensate properties compared to wild-type SS18. SS18-SSX1 condensates hijack wild-type SS18 condensates, relocating SS18 protein to H2AK119ub-marked loci targeted by SS18-SSX1, leading to downregulation of tumor suppressor genes (CAV1, DAB2) normally occupied by SS18.\",\n      \"method\": \"Small-molecule screening, mutant assays, live-cell condensate imaging, histone modification ChIP, gene expression analysis\",\n      \"journal\": \"Oncogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Weak — condensate imaging plus ChIP plus mutant assays, single lab, single study\",\n      \"pmids\": [\"39468035\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"H3K27ac deposition guides rapid relocation of SS18/BAF complexes from pluripotent loci to AP-1 (JUN)-associated loci during JUN-induced pluripotent-to-somatic transition. The direct interaction between SS18/BAFs and JUN-centric protein complexes is undetectable by IP-MS, indicating H3K27ac acts as an indirect signal for BAF redistribution.\",\n      \"method\": \"ChIP-seq, ATAC-seq, IP-MS, BRG1 knockdown, JUN-inducible PST system\",\n      \"journal\": \"Cell & bioscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — multiple genomic methods plus IP-MS negative result, single lab\",\n      \"pmids\": [\"35710570\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SS18-SSX can activate oncogenic transcription independently of BAF complex ATPase activity. Targeted degradation of BAF ATPase subunits (SMARCA4) has modest effects on sarcoma cell viability and does not impede SS18-SSX target gene expression. SS18-SSX promotes transcription by engaging the histone acetyltransferase EP300 independently of BAF, and this activity depends on the C-terminal QPGY-rich domain of SS18.\",\n      \"method\": \"Targeted degradation of BAF ATPase subunits, SMARCA4 deletion in mouse tumor model, domain-specific SS18-SSX mutants, EP300 Co-IP, pharmacologic EP300/CREBBP degradation with functional readout\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods including in vivo mouse model and domain mutagenesis; preprint not yet peer-reviewed\",\n      \"pmids\": [\"41659547\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CBX4 (chromobox 4), a canonical polycomb repressive complex member, is a novel interactor of the SS18-SSX fusion oncoprotein, identified by immunoprecipitation-mass spectrometry using a fusion-junction-specific antibody across six synovial sarcoma cell lines.\",\n      \"method\": \"Immunoprecipitation-mass spectrometry using SS18-SSX fusion-junction antibody across 6 SS cell lines, immunohistochemistry on tissue microarray\",\n      \"journal\": \"Laboratory investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — MS-based interactome with endogenous protein across multiple cell lines, single lab, no functional validation reported in abstract\",\n      \"pmids\": [\"40992545\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Proximity ligation assay (PLA) demonstrates physical interaction between SS18-SSX and the BAF complex member BRG1 in synovial sarcoma cells. ChIP with the SS18-SSX fusion-specific antibody confirms SS18-SSX occupancy at target gene promoters (TLE1, BCL2).\",\n      \"method\": \"Proximity ligation assay, chromatin immunoprecipitation with SS18-SSX fusion-junction-specific antibody\",\n      \"journal\": \"Applied immunohistochemistry & molecular morphology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Weak — PLA and ChIP, single lab, confirmatory rather than novel\",\n      \"pmids\": [\"35880992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SS18-SSX drives YAP/TAZ-TEAD transcriptional activity via an IGF-II/IGF-IR signaling loop that dysregulates Hippo effectors LATS1 and MOB1. RNAi knockdown of SS18-SSX reduces YAP/TAZ-TEAD transcriptional activity; conversely, SS18-SSX overexpression in mesenchymal stem cells induces aberrant YAP/TAZ-dependent signals.\",\n      \"method\": \"RNAi knockdown, SS18-SSX overexpression in mesenchymal stem cells, luciferase reporter for YAP/TAZ-TEAD, inhibitor treatment in vitro and in vivo xenograft/CAM models\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Weak — functional KD and OE with reporter and pathway assays, in vivo confirmation, single lab\",\n      \"pmids\": [\"30814111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"SUMO2 inhibition by TAK-981 reduces global expression levels and chromatin occupancy of the SS18-SSX fusion protein with a concomitant reduction in H2AK119 ubiquitination (H2AK119ub), an epigenetic mark facilitating synovial sarcoma pathogenesis.\",\n      \"method\": \"CRISPR library screening, SUMO2 genetic depletion, TAK-981 pharmacologic inhibition, transcriptomic profiling, ChIP analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR screen plus genetic and pharmacologic validation plus ChIP; single lab\",\n      \"pmids\": [\"40804185\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SS18 is a BAF-subtype-specific subunit of mammalian SWI/SNF (mSWI/SNF) chromatin remodeling complexes that undergoes liquid-liquid phase separation through its intrinsically disordered QPGY domain to recruit BRG1 and facilitate BAF assembly, and whose N-terminal 70 aa mediate BAF interaction; the oncogenic SS18-SSX fusion protein competes with wild-type SS18 for BAF incorporation, drives whole-complex degradation of canonical BAF (CBAF), globally retargets residual BAF complexes from enhancers to polycomb-repressed bivalent loci via interactions with KDM2B-PRC1.1 and TCF/LEF-TLE-HDAC complexes, activates Sox2 and other developmental genes, and can also activate transcription independently of BAF through recruitment of the histone acetyltransferase EP300 via its QPGY domain, while additionally promoting oncogenesis through ATF2-TLE1-mediated repression of anti-apoptotic genes, HDM2 stabilization, YAP/TAZ pathway activation, and SUMOylation-dependent maintenance of its chromatin occupancy.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"SS18 is a BAF-subtype-specific subunit of mammalian SWI/SNF (mSWI/SNF) chromatin remodeling complexes, co-purifying exclusively with ARID1A/ARID1B-containing BAF (not PBAF) complexes [#3]. It nucleates BAF assembly through two complementary modules: its N-terminal ~70 residues mediate direct interaction with the complex, while its C-terminal intrinsically disordered QPGY domain, rich in tyrosines, drives liquid-liquid phase separation that recruits the BRG1 ATPase into nuclear condensates [#6, #8]; structurally, SS18 contacts BRG1 through a heterodimer interface, and both phase separation and BAF assembly are required for function [#6]. SS18 incorporation into BAF is developmentally regulated—it is exchanged for CREST at mitotic exit to form neuron-specific nBAF complexes, and SS18 loss in neural stem cells causes cell-cycle exit and self-renewal failure [#4]; germline disruption of Ss18 in mice causes embryonic lethality from placental vascular failure [#14]. The recurrent oncogenic SS18-SSX fusion subverts this biology: it competes with wild-type SS18 for BAF incorporation to form an altered complex lacking the tumor suppressor BAF47/SMARCB1 and drives whole-complex degradation of canonical BAF [#0, #7]. The fusion globally retargets residual BAF complexes from enhancers to polycomb-repressed bivalent domains, opposing PRC2 and activating developmental genes such as Sox2, in part through physical association with the KDM2B-PRC1.1 complex on unmethylated CpG islands [#0, #1, #5]. SS18-SSX additionally represses target genes by bridging ATF2 and TLE1/Groucho, silencing anti-apoptotic MCL1 and BCL2A1 [#2, #12], and engages TCF/LEF-TLE-HDAC complexes to activate Wnt targets independent of β-catenin [#13]. The fusion can also activate transcription independently of BAF ATPase activity by recruiting the histone acetyltransferase EP300 via the QPGY domain [#22]. Its chromatin occupancy is reinforced by WDR5-promoted H3K4 methylation and by SUMOylation of cBAF subunits, and is sustained by oncogenic engagement of YAP/TAZ-TEAD signaling and HDM2-mediated p53 destabilization [#11, #18, #19, #25, #26].\",\n  \"teleology\": [\n    {\n      \"year\": 2006,\n      \"claim\": \"Established that SS18 has an essential physiological role in development, answering whether the gene matters in vivo beyond its known fusion in sarcoma.\",\n      \"evidence\": \"Targeted Ss18 gene disruption in mice with placental histology and expression profiling\",\n      \"pmids\": [\"16926188\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism linking SS18 loss to vascular/chorio-allantoic failure not resolved\", \"Relationship of placental phenotype to BAF chromatin remodeling not established\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined SS18 as a BAF-restricted (not PBAF) mSWI/SNF subunit, fixing its position in the chromatin remodeling machinery.\",\n      \"evidence\": \"Tandem affinity purification/mass spectrometry with complex walking in human cells\",\n      \"pmids\": [\"22442726\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define which SS18 domains mediate BAF specificity\", \"Functional contribution of SS18 to remodeling activity not assayed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showed the oncogenic fusion acts as a repressive transcription factor scaffold, bridging ATF2 and TLE1 to silence target genes—an early mechanism for fusion-driven gene repression.\",\n      \"evidence\": \"Affinity purification/MS, reciprocal Co-IP, siRNA knockdown and expression profiling in SS cell lines\",\n      \"pmids\": [\"22439931\", \"22797074\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relationship between this repressive complex and BAF incorporation not integrated\", \"Genome-wide scope of ATF2/TLE1-mediated repression not mapped\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrated the core oncogenic mechanism: SS18-SSX competes with wild-type SS18 for BAF assembly, evicts BAF47/SMARCB1, and reverses polycomb repression at Sox2.\",\n      \"evidence\": \"Reciprocal Co-IP, ChIP-seq, RNAi, and overexpression rescue in synovial sarcoma cell lines\",\n      \"pmids\": [\"23540691\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide retargeting pattern not yet established\", \"Mechanism by which the altered complex evades polycomb not defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealed developmentally programmed SS18 subunit exchange (SS18→CREST forming nBAF), establishing SS18 as a regulator of neural stem cell self-renewal and differentiation.\",\n      \"evidence\": \"Proteomic BAF composition analysis and SS18 knockdown in neural stem cells and neurons\",\n      \"pmids\": [\"23785148\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signal triggering the SS18/CREST switch not identified\", \"Connection to phase-separation behavior of SS18 not addressed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Mapped the genome-wide consequence of the fusion: global redistribution of BAF from enhancers to broad polycomb domains, and engagement of KDM2B-PRC1.1, explaining bivalent developmental gene activation.\",\n      \"evidence\": \"ChIP-seq, ATAC-seq, RNA-seq, Co-IP, and KDM2B knockdown in primary tumors and SS cell lines\",\n      \"pmids\": [\"29861296\", \"29502955\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"BAF47 reassembly shown dispensable for proliferative arrest, leaving the relevant effector unclear\", \"How residual BAF is physically retargeted to polycomb loci not fully resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed the fusion drives degradation of the entire canonical BAF complex rather than selective subunit loss, reframing the basis of SMARCB1 reduction in synovial sarcoma.\",\n      \"evidence\": \"Mouse genetics, recombinant CBAF reconstitution, and quantitative proteomics of BAF subtypes\",\n      \"pmids\": [\"34078620\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Degradation machinery targeting CBAF not identified\", \"Why PBAF/GBAF are spared not mechanistically explained\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established phase separation as the assembly principle: SS18's tyrosine-rich C-terminal IDR forms condensates while the N-terminal 70 aa engages BAF, both required for the pluripotent-to-somatic transition.\",\n      \"evidence\": \"CRISPR whole-genome screen, domain-mutant rescue, live-cell condensate imaging, and BAF Co-IP\",\n      \"pmids\": [\"34215745\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of condensation versus direct binding to remodeling not separated\", \"In vivo relevance of condensates to endogenous BAF function not established\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Provided the structural and biophysical basis for SS18-BRG1 assembly, showing a defined heterodimer interface and tyrosine-driven LLPS that recruits BRG1, both required for transformation.\",\n      \"evidence\": \"Crystal structures of SS18/BRG1 subcomplexes, in vitro LLPS assays, tyrosine mutagenesis, and NIH3T3 transformation\",\n      \"pmids\": [\"35585082\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of the full SS18-containing BAF assembly not determined\", \"How SS18-SSX alters condensate composition not addressed here\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Linked condensate behavior to the fusion's targeting specificity: SS18-SSX condensates read H2AK119ub via the SSX moiety and hijack wild-type SS18 condensates to silence tumor suppressors.\",\n      \"evidence\": \"Small-molecule screening, mutant assays, live-cell condensate imaging, and histone-mark ChIP\",\n      \"pmids\": [\"39468035\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single study without independent replication\", \"Direct biophysical demonstration of H2AK119ub recognition by SSX not shown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified a BAF-ATPase-independent activation arm in which SS18-SSX recruits EP300 through the QPGY domain, separating fusion oncogenic transcription from remodeling activity.\",\n      \"evidence\": \"Targeted degradation of BAF ATPase subunits, SMARCA4 deletion in mouse tumors, domain mutants, and EP300 Co-IP (preprint)\",\n      \"pmids\": [\"41659547\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Preprint not yet peer-reviewed\", \"Relative contribution of EP300 versus BAF-dependent activity to tumor maintenance not quantified\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Uncovered cofactor and post-translational dependencies (WDR5-driven H3K4 methylation; SUMOylation) that sustain SS18-SSX chromatin occupancy, nominating druggable nodes.\",\n      \"evidence\": \"Co-IP, ChIP-seq, CRISPR screens, and pharmacologic degradation/inhibition (WDR5 PROTAC, TAK-981) with in vivo validation\",\n      \"pmids\": [\"40267190\", \"40804185\", \"41193430\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct versus indirect routes by which SUMOylation stabilizes fusion occupancy not fully separated\", \"Whether these dependencies are specific to the fusion or shared with wild-type SS18 unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How wild-type SS18 condensation and BAF assembly are physiologically regulated across tissues, and how the fusion's multiple parallel mechanisms (BAF retargeting, EP300 recruitment, ATF2/TLE repression, YAP/TAZ and p53 axes) are integrated into a single transforming program, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified hierarchy ranking the fusion's mechanistic arms\", \"Cytosolic/actin-associated roles of SS18 (idx 15) not reconciled with nuclear BAF function\", \"Regulation of endogenous SS18 condensate dynamics in normal development not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 2, 12, 13, 22]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [6, 8]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [3, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 8, 17]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [8, 20]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [15]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [0, 1, 3, 5]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 12, 13, 22]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [4, 14]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 7]}\n    ],\n    \"complexes\": [\n      \"BAF (canonical mSWI/SNF)\",\n      \"nBAF (neuron-specific BAF)\",\n      \"KDM2B-PRC1.1\",\n      \"ATF2-TLE1 repressor complex\"\n    ],\n    \"partners\": [\n      \"SMARCA4\",\n      \"ARID1A\",\n      \"ATF2\",\n      \"TLE1\",\n      \"KDM2B\",\n      \"EP300\",\n      \"WDR5\",\n      \"TCF/LEF\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}